Eliana Clark - Jan 3, 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 3, 2024
Transactions value $
-$135,954
Form type
4
Date filed
1/5/2024, 04:44 PM
Previous filing
Jul 6, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$9.25K -307 -0.68% $30.12 45.1K Jan 3, 2024 Direct F1
transaction NTLA Common Stock Sale -$127K -4.3K -9.53% $29.46 40.8K Jan 3, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of 307 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2023.
F2 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person.